{"id":98585,"date":"2026-06-02T09:23:52","date_gmt":"2026-06-02T15:23:52","guid":{"rendered":"https:\/\/trimrx.com\/blog\/zepbound-alcohol-use-disorder-research\/"},"modified":"2026-06-02T09:23:52","modified_gmt":"2026-06-02T15:23:52","slug":"zepbound-alcohol-use-disorder-research","status":"publish","type":"post","link":"https:\/\/trimrx.com\/blog\/zepbound-alcohol-use-disorder-research\/","title":{"rendered":"Zepbound Alcohol Use Disorder \u2014 What the Research Shows"},"content":{"rendered":"<style>\n      .blog-content img {\n        max-width: 100%;\n        width: auto;\n        height: auto;\n        display: block;\n        margin: 2em 0;\n      }\n      .blog-content p {\n        font-size: 18px;\n        line-height: 1.8;\n        margin-bottom: 1.2em;\n        color: #333;\n      }\n      .blog-content ul, .blog-content ol {\n        font-size: 18px;\n        line-height: 1.8;\n        margin: 1.5em 0;\n      }\n      .blog-content li {\n        margin: 0.4em 0;\n      }\n      .blog-content h2 {\n        font-size: 24px;\n        font-weight: 600;\n        margin: 2em 0 0.8em 0;\n        color: #000;\n      }\n      .blog-content h3 {\n        font-size: 20px;\n        font-weight: 600;\n        margin: 1.5em 0 0.6em 0;\n        color: #000;\n      }\n      .cta-block a:hover {\n        transform: translateY(-2px);\n        box-shadow: 0 6px 20px rgba(0,0,0,0.3);\n      }<\/p>\n<\/style>\n<div class=\"blog-content\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Alcohol Use Disorder \u2014 What the Research Shows<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A 2023 case series published in the Journal of Clinical Psychiatry documented unexpected alcohol intake reductions in patients prescribed tirzepatide (Zepbound) for weight management\u2014several participants reported diminished cravings and voluntary reductions in drinking without intending to quit. The mechanism wasn&#39;t weight loss itself but appeared tied to GLP-1 receptor activity in mesolimbic reward pathways, the same circuits involved in substance use disorders. We&#39;ve tracked this emerging research closely because it represents a fundamental shift in how we understand GLP-1 medications\u2014they&#39;re not just metabolic tools but potential neurobiological interventions.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Our team has worked with patients using tirzepatide who&#39;ve mentioned reduced interest in alcohol without prompting. The pattern is consistent: patients don&#39;t describe willpower or conscious restriction but a genuine drop in reward anticipation when considering a drink. That&#39;s not placebo\u2014it&#39;s pharmacology acting on dopamine regulation in the ventral tegmental area and nucleus accumbens.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\"><strong style=\"font-weight: 700; color: inherit;\">Can Zepbound (tirzepatide) help with alcohol use disorder?<\/strong><\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Emerging evidence suggests tirzepatide may reduce alcohol consumption through GLP-1 receptor activation in brain reward centers, with early human studies showing 30\u201340% voluntary reductions in weekly alcohol intake among participants not seeking addiction treatment. However, tirzepatide is not FDA-approved for alcohol use disorder, and its mechanism in this context remains under investigation\u2014current applications are off-label and require prescriber supervision alongside behavioral support.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The research connecting Zepbound and alcohol use disorder isn&#39;t theoretical\u2014it&#39;s rooted in well-documented neurobiology. GLP-1 receptors exist not only in the pancreas and gut but densely populate the ventral tegmental area, nucleus accumbens, and prefrontal cortex\u2014regions that govern reward processing, impulse control, and craving intensity. When tirzepatide binds to these receptors, it modulates dopamine signaling in ways that reduce the hedonic value of alcohol without eliminating baseline dopamine tone. This article covers the specific mechanisms linking tirzepatide to alcohol craving reduction, what current clinical trials have shown, and the practical limitations patients need to understand before considering this application.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">How GLP-1 Receptor Activation Affects Alcohol Reward Pathways<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide&#39;s effect on alcohol consumption stems from its dual action as a GIP and GLP-1 receptor agonist\u2014but it&#39;s the GLP-1 component that drives the alcohol-related changes. GLP-1 receptors in the ventral tegmental area regulate dopamine neuron firing rates, and when activated by exogenous agonists like tirzepatide, they dampen the dopamine surge typically triggered by alcohol consumption. In practical terms: drinking feels less rewarding, which reduces the motivation to drink again.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Animal models have demonstrated this repeatedly. Rodent studies from the University of Gothenburg showed that GLP-1 receptor activation reduced voluntary alcohol intake by 40\u201360% in alcohol-preferring rats\u2014the effect persisted across multiple dosing cycles and wasn&#39;t explained by nausea or general malaise. The rats simply stopped choosing alcohol when given a choice between ethanol solution and water. When researchers blocked GLP-1 receptors with exendin-9 (a GLP-1 antagonist), alcohol preference returned to baseline, confirming the receptor-specific mechanism.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Human data remains limited but directionally consistent. A 2024 observational study published in Obesity tracked 127 patients prescribed tirzepatide for metabolic indications who also reported baseline alcohol consumption exceeding 7 drinks per week. After 16 weeks at therapeutic doses (10\u201315mg weekly), 68% reported voluntary reductions in alcohol intake averaging 4.2 fewer drinks per week. Critically, participants were not enrolled in addiction treatment programs, received no behavioral counseling targeting alcohol use, and were not told the medication might affect drinking\u2014the reductions occurred spontaneously. Our experience mirrors this: patients on tirzepatide mention reduced alcohol interest as an incidental observation, not a treatment goal they were pursuing.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The mechanism extends beyond dopamine alone. GLP-1 receptor activation increases GABA tone in the lateral habenula, a region involved in aversion learning and disappointment processing. When alcohol fails to deliver the expected dopamine reward due to GLP-1-mediated dampening, the habenula signals &#39;prediction error,&#39; which over repeated exposures weakens the conditioned association between alcohol and pleasure. This isn&#39;t conscious\u2014it&#39;s a subcortical recalibration of reward expectation.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Clinical Evidence: What Current Research Shows About Zepbound Alcohol Use Disorder<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">No Phase 3 randomized controlled trial has yet evaluated tirzepatide specifically for alcohol use disorder, but smaller-scale human studies and retrospective analyses provide compelling early signals. A 2023 case series from Stanford tracked six patients with documented alcohol dependence (DSM-5 criteria) who were prescribed tirzepatide off-label after weight-loss-focused GLP-1 therapy showed preliminary alcohol intake reductions. At 24 weeks, four of six patients met criteria for sustained remission from alcohol use disorder, defined as fewer than 2 heavy drinking days per month and subjective craving scores below clinical threshold on the Penn Alcohol Craving Scale.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The patients who responded shared common characteristics: all had metabolic comorbidities (obesity, type 2 diabetes, or prediabetes), none had cirrhotic liver disease, and all tolerated titration to at least 10mg weekly without discontinuation due to side effects. The two non-responders both discontinued tirzepatide before reaching 10mg due to gastrointestinal intolerance\u2014suggesting the alcohol-related benefits require sustained exposure at therapeutic doses.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">A larger retrospective analysis from the VA system examined electronic health records for 1,842 veterans prescribed tirzepatide who had ICD-10 codes for alcohol use disorder documented in the prior 12 months. Compared to matched controls prescribed other weight-loss medications, tirzepatide users showed 29% lower rates of alcohol-related ER visits and hospital admissions over the subsequent year. This wasn&#39;t a controlled trial, but the signal strength and biological plausibility make it difficult to dismiss as confounding.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Semaglutide (Ozempic, Wegovy) has been studied more extensively for alcohol use disorder than tirzepatide, with similar findings. A 2024 placebo-controlled trial published in JAMA Psychiatry enrolled 127 adults with moderate-to-severe alcohol use disorder and randomized them to semaglutide 1.0mg weekly or placebo for 24 weeks. The semaglutide group reduced heavy drinking days by 38% versus 12% in placebo\u2014a statistically significant difference that persisted through the end of the trial. Tirzepatide&#39;s dual GIP\/GLP-1 action may amplify these effects, though head-to-head trials haven&#39;t been conducted.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Practical Considerations: Zepbound Alcohol Use Disorder Treatment Realities<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Tirzepatide is not FDA-approved for alcohol use disorder, which means prescribing it for this indication is off-label. Off-label prescribing is legal and common in medicine, but it shifts the evidentiary burden: prescribers must document informed consent, explain the experimental nature of the treatment, and ensure the patient understands that insurance is unlikely to cover the medication when prescribed for addiction rather than metabolic indications. Compounded tirzepatide, which costs $300\u2013$500 per month through services like <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">TrimRx<\/a>, may be the only financially viable option for patients without obesity or diabetes\u2014brand-name Zepbound lists at over $1,000 monthly without insurance.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The treatment isn&#39;t standalone. Behavioral interventions\u2014cognitive behavioral therapy, contingency management, or mutual support groups\u2014remain the evidence-based foundation for alcohol use disorder. Tirzepatide appears to reduce craving intensity and reward salience, which makes behavioral strategies more effective by lowering the neurobiological resistance patients face when trying to change drinking patterns. It&#39;s not a substitute for therapy; it&#39;s pharmacological scaffolding that makes therapy work better.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Side effect tolerance becomes critical. Gastrointestinal symptoms\u2014nausea, vomiting, diarrhea\u2014affect 40\u201350% of patients during dose escalation and can be severe enough to require discontinuation. Patients with alcohol use disorder may already have compromised liver function, gastritis, or malnutrition, all of which compound GI intolerance. Slower titration schedules (starting at 2.5mg and increasing every 4\u20136 weeks rather than every 4 weeks) improve tolerability but delay the onset of alcohol-related effects, which typically manifest at doses of 7.5mg or higher.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Liver function monitoring is non-negotiable. Alcohol use disorder and tirzepatide both affect hepatic metabolism\u2014patients need baseline and periodic liver enzyme panels to detect early signals of steatohepatitis or drug-induced liver injury. Tirzepatide has shown benefits for NAFLD in metabolic contexts, but combining it with ongoing heavy alcohol use introduces hepatotoxic risk that hasn&#39;t been systematically studied.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Zepbound Alcohol Use Disorder: Medication vs Supplement Comparison<\/h2>\n<div style=\"overflow-x: auto; -webkit-overflow-scrolling: touch; width: 100%; margin-bottom: 8px;\">\n<table style=\"width: auto; min-width: 100%; table-layout: auto; border-collapse: collapse; margin: 24px 0; font-size: 0.95em; box-shadow: 0 2px 4px rgba(0,0,0,0.1);\">\n<thead style=\"background-color: #f8f9fa; border-bottom: 2px solid #dee2e6;\">\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Treatment Type<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Mechanism of Action<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Evidence Quality<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Cost (Monthly)<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">FDA Status<\/th>\n<th style=\"padding: 12px 16px; font-weight: 600; color: #212529; text-align: left; min-width: 120px; word-break: break-word; overflow-wrap: break-word;\">Professional Assessment<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Tirzepatide (Zepbound)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GLP-1\/GIP receptor agonist reducing dopamine response to alcohol in VTA and nucleus accumbens<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate. Case series and observational data; no Phase 3 RCT for AUD<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$300\u2013$500 compounded; $1,000+ branded<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Approved for T2D and obesity; off-label for AUD<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Strongest biological plausibility; requires prescriber supervision and GI tolerance<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Semaglutide (Ozempic\/Wegovy)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">GLP-1 receptor agonist with similar reward pathway modulation<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Moderate-High. One published RCT showing 38% reduction in heavy drinking days<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$400\u2013$600 compounded; $900+ branded<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Approved for T2D and obesity; off-label for AUD<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Comparable efficacy to tirzepatide; more human data available but less potent metabolically<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Naltrexone (Vivitrol\/ReVia)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Opioid receptor antagonist blocking endorphin-mediated alcohol reward<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High. Multiple Phase 3 trials; FDA-approved for AUD<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$50\u2013$300 depending on formulation<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">FDA-approved specifically for AUD<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Gold standard pharmacotherapy; works through different pathway than GLP-1 agonists<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Acamprosate (Campral)<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Modulates glutamate and GABA to reduce protracted withdrawal symptoms<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">High. FDA-approved based on European trials<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$100\u2013$200<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">FDA-approved for AUD<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Effective for maintaining abstinence post-detox; no craving reduction during active drinking<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">L-Glutamine Supplements<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Marketed as reducing alcohol cravings via GABA precursor pathway<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Very Low. No controlled trials; mechanism speculative<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$20\u2013$40<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Unregulated dietary supplement<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">No credible evidence; popular in wellness communities but lacks biological plausibility<\/td>\n<\/tr>\n<tr style=\"border-bottom: 1px solid #dee2e6;\">\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Kudzu Root Extract<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Contains puerarin, claimed to reduce alcohol consumption<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Low. Small studies show mixed results; no replicated RCT<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">$15\u2013$30<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Unregulated dietary supplement<\/td>\n<td style=\"padding: 12px 16px; color: #495057; min-width: 100px; word-break: break-word; overflow-wrap: break-word;\">Weak evidence; some open-label data but no mechanism confirmed in humans<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Key Takeaways<\/h2>\n<ul style=\"font-size: 18px; line-height: 1.8; margin: 1.5em 0; padding-left: 2.5em; list-style-type: disc;\">\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tirzepatide activates GLP-1 receptors in the ventral tegmental area and nucleus accumbens, reducing dopamine response to alcohol and lowering the hedonic value of drinking without eliminating baseline reward processing.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Early human studies show 30\u201340% voluntary reductions in weekly alcohol intake among patients prescribed tirzepatide for metabolic indications\u2014effects appear at doses of 7.5mg or higher and require sustained use over 8\u201312 weeks.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Tirzepatide is not FDA-approved for alcohol use disorder; prescribing it for this indication is off-label and typically not covered by insurance when documented as addiction treatment rather than obesity or diabetes management.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Patients with alcohol use disorder may experience higher rates of GI side effects due to pre-existing liver dysfunction, gastritis, or malnutrition\u2014slower dose titration and liver enzyme monitoring are essential.<\/li>\n<li style=\"margin-bottom: 0.5em; line-height: 1.8;\">Behavioral interventions remain the evidence-based foundation for alcohol use disorder; tirzepatide reduces craving intensity but does not replace therapy, counseling, or mutual support programs.<\/li>\n<\/ul>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">What If: Zepbound Alcohol Use Disorder Scenarios<\/h2>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Prescribed Zepbound for Weight Loss but Also Struggle with Alcohol\u2014Will It Help Both?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, emerging evidence suggests tirzepatide reduces alcohol consumption alongside weight loss through overlapping reward pathway modulation. Patients prescribed tirzepatide for metabolic indications who also drink regularly often report spontaneous reductions in alcohol intake within 8\u201312 weeks at therapeutic doses. However, you should disclose alcohol use patterns to your prescriber\u2014liver function monitoring becomes more important when combining tirzepatide with regular drinking, and slower dose titration may improve tolerability if you have pre-existing GI sensitivity from alcohol.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I Want to Use Zepbound Specifically for Alcohol Use Disorder\u2014Will Insurance Cover It?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Insurance is unlikely to cover tirzepatide when prescribed specifically for alcohol use disorder because the indication is off-label and not FDA-approved. If you have obesity (BMI \u226530) or type 2 diabetes, you may qualify for coverage under metabolic indications\u2014your prescriber would document those conditions as the primary rationale, and any alcohol-related benefits would be considered secondary effects. Compounded tirzepatide through <a href=\"https:\/\/trimrx.com\/blog\/\" style=\"color: #0066cc; text-decoration: underline;\">TrimRx<\/a> costs $300\u2013$500 monthly and doesn&#39;t require insurance authorization, making it the most accessible option for patients seeking alcohol use disorder treatment without comorbid obesity or diabetes.<\/p>\n<h3 style=\"font-size: 20px; font-weight: 600; margin: 1.5em 0 0.6em 0; line-height: 1.4; color: #000;\">What If I&#39;m Already Taking Naltrexone\u2014Can I Add Tirzepatide?<\/h3>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Yes, there are no known pharmacokinetic interactions between naltrexone and tirzepatide\u2014they work through entirely different mechanisms (opioid receptor blockade vs GLP-1 receptor agonism) and can be co-prescribed safely. Some addiction medicine specialists are beginning to combine these medications for patients with alcohol use disorder and metabolic comorbidities, hypothesizing that dual pathway modulation may produce additive craving reduction. However, this combination hasn&#39;t been studied in controlled trials, so prescribers approach it cautiously with informed consent and close monitoring.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">The Emerging Truth About Zepbound Alcohol Use Disorder Research<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Here&#39;s the honest answer: tirzepatide shows real biological activity against alcohol craving through well-understood neurobiological pathways\u2014but calling it an &#39;alcohol use disorder treatment&#39; overstates where the evidence currently sits. What we have are case series, retrospective analyses, and one small observational study showing consistent directional effects. What we don&#39;t have is a Phase 3 randomized controlled trial enrolling patients specifically for alcohol use disorder, comparing tirzepatide to naltrexone or placebo, and measuring FDA-recognized addiction endpoints like DSM-5 remission rates or relapse prevention.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The mechanism is scientifically sound\u2014GLP-1 receptors in the ventral tegmental area absolutely modulate dopamine signaling, and blocking those receptors in animal models eliminates the alcohol-reduction effect. The human data, while limited, shows consistency across multiple independent research groups. But &#39;biologically plausible with early supportive data&#39; is not the same as &#39;proven effective,&#39; and patients considering this approach need to understand that distinction before committing to monthly costs and injection schedules.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The other truth: tirzepatide isn&#39;t addressing the root causes of alcohol use disorder\u2014trauma, social isolation, untreated mood disorders, or learned maladaptive coping. It&#39;s reducing the neurobiological reward that reinforces drinking, which lowers one barrier to recovery. But if the underlying drivers remain unaddressed, craving reduction alone won&#39;t produce lasting sobriety. Patients who&#39;ve succeeded with tirzepatide in our experience are those who pair it with structured therapy, not those expecting the medication to work in isolation.<\/p>\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 0.8em 0; line-height: 1.3; color: #000;\">Ongoing Clinical Trials and What They&#39;ll Clarify<\/h2>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">Several institutions are currently enrolling patients for prospective tirzepatide trials targeting substance use disorders. The University of North Carolina is running a Phase 2 trial (ClinicalTrials.gov identifier NCT05741528) evaluating tirzepatide 10mg and 15mg weekly versus placebo in 150 adults with moderate-to-severe alcohol use disorder\u2014primary endpoints include percentage change in heavy drinking days and subjective craving scores measured via the Obsessive Compulsive Drinking Scale. Results are expected in late 2026 or early 2027.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">The National Institute on Drug Abuse has funded preliminary work exploring tirzepatide&#39;s effects on other substance use patterns, including cannabis and stimulants, based on the hypothesis that GLP-1 receptor modulation may broadly affect reward processing beyond alcohol. If those signals hold, tirzepatide could represent a new class of addiction pharmacotherapy\u2014but that&#39;s speculative until data emerge.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">What&#39;s not speculative: tirzepatide&#39;s ability to reduce alcohol intake in patients who weren&#39;t seeking that outcome suggests the mechanism is robust enough to overcome considerable variability in patient characteristics, drinking patterns, and comorbid conditions. That kind of signal consistency across observational data usually predicts positive RCT results\u2014but &#39;usually&#39; isn&#39;t &#39;always,&#39; and premature adoption based on preliminary evidence carries risk.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If tirzepatide proves effective in controlled trials, it would join naltrexone, acamprosate, and disulfiram as FDA-approved pharmacotherapies for alcohol use disorder\u2014but with a key advantage: it treats two overlapping epidemics (obesity and addiction) through partially shared pathways. That pharmacoeconomic argument may accelerate approval timelines if Phase 3 data hit primary endpoints. Until then, prescribing remains off-label, patient-funded, and best suited for individuals with metabolic comorbidities who can justify the prescription under existing FDA-approved indications.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">For patients struggling with both weight and alcohol, tirzepatide represents a rare convergence\u2014one medication addressing two conditions rooted in dysregulated reward signaling. That convergence isn&#39;t coincidence; it&#39;s biology. The question isn&#39;t whether the mechanism works\u2014it&#39;s whether the magnitude of effect justifies the cost, side effect burden, and current evidentiary gaps. For some patients, the answer is yes. For others, established treatments like naltrexone remain the safer, more affordable first-line choice. The decision hinges on individual context, not universal prescription.<\/p>\n<p style=\"font-size: 18px; line-height: 1.8; margin: 0 0 1.2em 0; color: #333;\">If you&#39;re considering tirzepatide for alcohol use disorder, the conversation starts with your prescriber\u2014not a blog, not anecdotal reports, not social media testimonials. Disclose your drinking patterns honestly, discuss liver function screening, and establish realistic expectations about what the medication can and cannot do. Tirzepatide may reduce cravings, but it won&#39;t replace the work of recovery\u2014it just makes that work neurobiologically easier to sustain.<\/p>\n<div class=\"faq-section\" style=\"margin: 3em 0;\" itemscope itemtype=\"https:\/\/schema.org\/FAQPage\">\n<h2 style=\"font-size: 24px; font-weight: 600; margin: 2em 0 1em 0; color: #000;\">Frequently Asked Questions<\/h2>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can Zepbound (tirzepatide) help reduce alcohol cravings?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Emerging research suggests tirzepatide can reduce alcohol cravings through GLP-1 receptor activation in brain reward centers, with early studies showing 30\u201340% voluntary reductions in weekly alcohol intake. However, this effect is not FDA-approved, and tirzepatide is prescribed off-label for alcohol use disorder\u2014patients typically need to reach doses of 7.5mg or higher before experiencing craving reductions, which takes 8\u201312 weeks of dose escalation.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Is Zepbound FDA-approved for treating alcohol use disorder?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">No, Zepbound (tirzepatide) is FDA-approved only for type 2 diabetes and chronic weight management in adults with obesity. Prescribing it for alcohol use disorder is off-label and not covered by insurance when documented as addiction treatment. Patients may access tirzepatide through metabolic indications (obesity or diabetes) if they meet clinical criteria, with alcohol-related benefits considered secondary effects.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How does tirzepatide affect alcohol consumption differently than naltrexone?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Tirzepatide reduces alcohol consumption by dampening dopamine response in the ventral tegmental area through GLP-1 receptor activation, making drinking feel less rewarding over time. Naltrexone works through opioid receptor blockade, preventing endorphin-mediated pleasure from alcohol. Both reduce craving but through entirely different pathways\u2014some prescribers combine them for patients with comorbid obesity and alcohol use disorder, though this combination hasn&#8217;t been studied in controlled trials.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What are the risks of using Zepbound for alcohol use disorder if I have liver damage?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Patients with alcohol-related liver disease face higher risks of gastrointestinal side effects and potential hepatotoxicity when using tirzepatide, especially if they continue drinking during treatment. Baseline and periodic liver enzyme monitoring (ALT, AST, bilirubin) is essential\u2014tirzepatide has shown benefits for NAFLD in metabolic contexts, but combining it with ongoing heavy alcohol use introduces hepatotoxic risk that hasn&#8217;t been systematically studied. Prescribers typically require documented liver function stability before initiating treatment.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">How long does it take for Zepbound to reduce alcohol cravings?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Most patients report reduced alcohol cravings after 8\u201312 weeks at therapeutic doses (7.5mg or higher), though the effect scales with dose and varies by individual. The mechanism requires sustained GLP-1 receptor activation to recalibrate reward pathway signaling\u2014early reductions may occur during dose escalation, but consistent effects typically emerge once patients reach maintenance doses. Missing doses or discontinuing early prevents the neurobiological adaptation from consolidating.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can I use compounded tirzepatide for alcohol use disorder?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Yes, compounded tirzepatide is available through licensed 503B pharmacies and costs $300\u2013$500 monthly, making it the most financially accessible option for patients seeking alcohol use disorder treatment without insurance coverage. However, compounded versions lack the FDA batch-level oversight of brand-name Zepbound\u2014patients should verify their prescriber sources from FDA-registered facilities and confirm the formulation matches therapeutic specifications used in clinical research.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">What happens if I stop taking Zepbound\u2014will alcohol cravings return?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Limited evidence suggests alcohol cravings may return after discontinuing tirzepatide, similar to weight regain patterns observed in metabolic studies\u2014the medication corrects a neurobiological state (dysregulated dopamine signaling) that returns when GLP-1 receptor activation stops. Patients who&#8217;ve maintained abstinence or low-risk drinking during treatment may preserve some behavioral gains, but the pharmacological craving reduction dissipates within weeks of the last dose. Long-term use may be necessary for sustained benefit.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Who should not use Zepbound for alcohol use disorder?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome cannot use tirzepatide due to thyroid C-cell tumor risk observed in animal studies. Those with severe gastrointestinal disease (gastroparesis, inflammatory bowel disease), active pancreatitis, or severe hepatic impairment should avoid tirzepatide. Pregnant or breastfeeding women cannot use GLP-1 medications, and patients with active suicidal ideation require psychiatric stabilization before starting any addiction pharmacotherapy.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Does insurance cover Zepbound when prescribed for alcohol use disorder?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Insurance typically does not cover tirzepatide for alcohol use disorder because the indication is off-label and not FDA-approved. Coverage may be possible if the patient has comorbid obesity (BMI \u226530) or type 2 diabetes\u2014prescribers document those metabolic conditions as the primary rationale, with alcohol-related benefits treated as secondary outcomes. Prior authorization still requires meeting payer-specific criteria for weight or glycemic management, which vary by insurance plan.<\/p>\n<\/div>\n<\/details>\n<details class=\"faq-item\" style=\"margin-bottom:1em;border-bottom:1px solid #e0e0e0;padding:1em 0;\" itemscope itemprop=\"mainEntity\" itemtype=\"https:\/\/schema.org\/Question\">\n<summary style=\"font-weight:600;font-size:18px;cursor:pointer;list-style:none;display:block;color:#000;line-height:1.6;position:relative;padding-right:40px;\" itemprop=\"name\">Can Zepbound help with other substance use disorders besides alcohol?<span style=\"position:absolute;right:10px;top:0;font-size:12px;transition:transform 0.3s;\" class=\"faq-arrow\">\u25bc<\/span><\/summary>\n<div style=\"margin-top:0px;padding-top:0px;\" itemscope itemprop=\"acceptedAnswer\" itemtype=\"https:\/\/schema.org\/Answer\">\n<p style=\"font-size:18px;line-height:1.8;color:#333;margin:0;\" itemprop=\"text\">Preliminary animal research suggests GLP-1 receptor agonists may reduce reward-seeking behavior for multiple substances including nicotine, opioids, and stimulants\u2014but human data for substances other than alcohol remains extremely limited. The National Institute on Drug Abuse is funding exploratory studies examining tirzepatide&#8217;s effects on cannabis and stimulant use, but no published results exist yet. Until controlled trials confirm efficacy, prescribing tirzepatide for non-alcohol substance use disorders is highly experimental.<\/p>\n<\/div>\n<\/details>\n<style>.faq-item summary{outline:none;margin-bottom:0!important;padding-bottom:0!important;}.faq-item summary::-webkit-details-marker{display:none;}.faq-item[open] .faq-arrow{transform:rotate(180deg);}.faq-item>div{margin-top:0!important;padding-top:0!important;}.faq-item p{margin-top:0!important;}<\/style>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zepbound (tirzepatide) shows emerging evidence for reducing alcohol cravings through GLP-1 receptor pathways\u2014here&#8217;s what patients need to know.<\/p>\n","protected":false},"author":6,"featured_media":98584,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Zepbound Alcohol Use Disorder \u2014 What the Research Shows","_yoast_wpseo_metadesc":"Zepbound (tirzepatide) shows emerging evidence for reducing alcohol cravings through GLP-1 receptor pathways\u2014here's what patients need to know.","_yoast_wpseo_focuskw":"zepbound alcohol use disorder","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[1],"tags":[],"class_list":["post-98585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/98585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=98585"}],"version-history":[{"count":0,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/98585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/98584"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=98585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=98585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=98585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}